LC
CHRS icon

Lindbrook Capital’s Coherus Oncology CHRS Stock Holding History

Lindbrook Capital’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-486
Closed -$1.82K – 2711
2023
Q3 		$1.82K Buy
486
+111
+30% +$513 ﹤0.01% 2162
2023
Q2 		$1.6K Buy
+375
New +$2.21K ﹤0.01% 2236
2022
Q4 		– Sell
-37
Closed – – 2855
2022
Q3 		$0 Buy
+37
New +$374 ﹤0.01% 2649
2022
Q2 		– Sell
-63
Closed -$1K – 2518
2022
Q1 		$1K Buy
+63
New +$801 ﹤0.01% 2190

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lindbrook Capital's CHRS Position: Q4 2023 in Review

Lindbrook Capital sold out of Coherus Oncology (CHRS) in Q4 2023, closing a stake of 486 shares — an estimated $1.82K sold.

Lindbrook Capital first reported a position in CHRS in Q1 2022 and held it in 4 quarters. The position peaked at $1.82K in Q3 2023. 156 funds tracked by Wall St. Rank hold CHRS as of Q4 2023.

  • Lindbrook Capital reported no remaining Coherus Oncology position as of Q4 2023 after selling out during the quarter.
  • Lindbrook Capital sold 486 Coherus Oncology shares in Q4 2023, an estimated $1.82K.
  • Lindbrook Capital first reported a position in Coherus Oncology in Q1 2022 and held it in 4 quarters.
  • Lindbrook Capital's Coherus Oncology position peaked at $1.82K in Q3 2023.
  • 156 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2023.

Based on Lindbrook Capital's 13F filing for Q4 2023, filed 1 Feb 2024.